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Laboratory Focus
“We are witnessing 
a revolution in the 
way we practice 
medicine—from what 
we understand about 
pathogenesis to how 
we predict, diagnose, 
and treat diseases.  
The challenge is to 
find that right balance 
between the molecular 
information we can 
collect against the 
information that is 
most beneficial to our 
individual patients.” 
–Jon Heusel, MD, 
Ph.D., UIHC Molecular Pathologist. This 
is the guiding principle that drives new 
test development in the UIHC Molecular 
Pathology Laboratory. 
Along with the recent addition of Dr. 
Deqin Ma to the Molecular Pathology (and 
Surgical Pathology) faculty Molecular 
Pathology has also hired a full-time 
Research Scientist, Natalya Guseva, 
Ph.D., to provide assistance in molecular 
test development.  
Dr. Guseva has over 20 years experience 
in molecular oncology and immunology 
Molecular Pathology Faculty Team:
Deqin Ma, MD, PhD, Aaron Bossler, MD, PhD 
(Director), Jonathan Heusel, MD, PhD, and 
Anthony Snow, MD (Fellow)
research, and has been instrumental in the 
validations of many molecular tests that 
have arrived on the Molecular Pathology 
testing menu over the last year (see list 
of recently added tests on page 6 of 
this issue).  The Molecular Pathology 
Laboratory Director, Dr. Aaron Bossler, 
credits the entire laboratory staff led 
by Jon Pruessner, Lead Scientist, with 
a ‘unified, focused effort to expand our 
testing while maintaining a very high 
degree of daily clinical testing service.  
These people are incredibly dedicated.’
The UIHC Molecular Pathology 
Laboratory has emphasized expansion of 
testing for targeted mutations in oncology 
(e.g., BRAF and KRAS mutation detection 
in colorectal cancer, and melanoma, 
quantitative BCR-ABL transcript detection 
for CML, CEBPA sequencing in AML, 
KIT sequencing for AML, melanoma 
and GIST, and NRAS mutation detection 
in melanoma) in part through ongoing 
dialogue with the Holden Comprehensive 
Cancer Center clinicians and investigators. 
The idea is to provide the tests that 
UIHC and regional Iowa physicians need 
most, and to assist in directing reference 
laboratory testing for those tests that are 
not provided on the current Molecular 
Pathology testing menu. 
Expansion of Test Development Capability –  
UIHC Molecular Pathology Lab
Continued on page 10
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especially apt to form the insertion-deletion loops normally 
repaired by an intact DNA MMR apparatus.  Microsatellite 
instability (MSI) is thus a phenotypic consequence of deficient 
MMR (dMMR) function, and polymerase-chain-reaction-based 
MSI testing is similarly sensitive in detecting LS.      
Clinical Relevance:
Patients with CRC in whom LS is diagnosed may be counseled 
to undergo a subtotal colectomy (as the risk of a second CRC 
in these patients is as high as 40%), and mutation-positive 
individuals benefit from intensive colonoscopic surveillance.  
They may also be entered into surveillance for other LS-
associated tumors, especially endometrial and urothelial cancer. 
Testing Strategies:
A variety of approaches to identify potential LS cancers have 
been employed, ranging in intensity from passive strategies 
(i.e., relying on clinicians to request testing) to universal ones 
(i.e., testing all CRC’s).  Other strategies take advantage of 
the characteristic clinical and/or pathologic features of LS-
associated tumors.  Unfortunately, the most widely publicized 
clinical criteria, the revised Bethesda guidelines and the 
Amsterdam criteria II, are relatively insensitive in population-
based screening.  There is increasing momentum for universal 
screening, which has been officially endorsed by the Evaluation 
of Genomic Applications in Practice and Prevention Working 
Group and the Association for Molecular Pathology.  Universal 
screening has been shown to have an incremental cost-
Lynch Syndrome Defined:  
Lynch syndrome (LS) is the most common cause of hereditary 
colorectal cancer (CRC), accounting for 2-4% of all CRC.  This 
highly penetrant autosomal dominant cancer syndrome is usually 
due to germline inactivating mutation in a DNA mismatch repair 
(MMR) gene (MLH1, PMS2, MSH2, MSH6), rarely due to EPCAM 
deletion, and exceptionally due to MLH1 or MSH2 epimutation 
(i.e., soma-wide, allele-specific promoter methylation).  The LS 
phenotype is characterized by early onset CRC, increased cancer 
risk at a defined set of extracolonic sites (i.e., endometrium, 
stomach, small intestine, ovary, upper urinary tract, brain, and 
skin [sebaceous tumors and keratoacanthomas]), and tendency for 
multiple tumors.  Two-thirds of LS-associated CRC’s are right-
sided, and tumors may demonstrate one or more characteristic 
histologic features including mucinous, medullary, or signet-
ring-cell differentiation; a prominent tumor-associated lymphoid 
response; and a pushing tumor front.    
DNA Mismatch Repair and Microsatellite Instability:
The DNA MMR apparatus recognizes and repairs mispaired 
bases and insertion-deletion loops.  Cancers in LS are associated 
with silencing of the wild-type allele, resulting in loss of 
expression of one or more of the mismatch repair proteins (see 
Image).  Immunostains for MLH1, PMS2, MSH2, and MSH6 
are commercially available, and MMR immunohistochemistry 
(IHC) has been shown to detect >90% of LS-associated CRC’s.  
Microsatellites are simple repetitive DNA sequences scattered 
throughout the genome.  During DNA replication they are 
University of Iowa Health Care Launches Universal Screening 
for Lynch Syndrome in Colorectal Cancer
*If clinically compelling, may refer to Cancer Genetics at any point in algorithm
Andrew M. Bellizzi, MD 
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Figure.  Iowa Lynch Syndrome Screening Algorithm in Colorectal Cancer
Key: MMR IHC, mismatch repair protein immunohistochemistry; MSI, microsatellite instability; MSI-H, high-level microsatellite instability
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effectiveness ratio on the order of that seen with screening 
colonoscopy for CRC.  MMR IHC and MSI testing, either alone 
or in combination, may be employed in LS screening. 
Sporadic Tumors with dMMR Function:
Fifteen (15) % of CRC’s are characterized by transcriptional 
silencing of MLH1 due to acquired promoter methylation.  These 
tumors are also identified by MMR IHC or MSI testing.  It is 
advantageous to identify this larger group of tumors because 
dMMR function is prognostically favorable and is associated 
with reduced sensitivity to 5-fluorouracil-based chemotherapy.  
Given these facts, medical oncologists are increasingly using 
the results of MMR IHC and/or MSI testing to help decide 
whether to recommend adjuvant chemotherapy in patients with 
stage II CRC.  Additional testing is useful in separating sporadic 
dMMR tumors from LS-associated ones.  Up to three-quarters 
of sporadic dMMR CRC’s have a BRAFV600E mutation, which 
essentially does not occur in MLH1-associated LS.  MLH1 
promoter methylation testing may also be used.   
University of Iowa Health Care Testing Algorithm: 
There was support for LS screening in CRC from 
Gastroenterology, Surgery, Medical Oncology, and Cancer 
Genetics, represented at the Holden Comprehensive Cancer 
Center Colorectal Cancer Tumor Board.  Given reasonable cost-
effectiveness, a strong desire to detect as many LS patients as 
possible, and the added benefit of identifying additional sporadic 
dMMR tumors, a universal screening strategy was adopted (see 
Figure).  MMR IHC, with the advantages of rapid turnaround 
time and ready application in biopsy material (without the need 
for matched normal DNA), was selected as the first screening 
test.  Most tumors (~85%) have normal MMR protein expression. 
To maximize the sensitivity of LS detection, in these cases MSI 
testing is performed on a resection specimen.  Very rare MSI-H 
tumors with preceding normal MMR IHC are likely LS due to a 
missense mutation in a MMR gene that silences MMR function 
without altering protein expression.  Approximately 15% of 
tumors will have an abnormal MMR IHC result.  Usually, this 
is absent expression of MLH1 and PMS2.  In these cases BRAF 
mutation testing is pursued to distinguish sporadic dMMR tumors 
from LS.  BRAF wild-type tumors require follow up (MLH1 
promoter methylation testing and/or referral to Cancer Genetics). 
Tumors with other patterns of abnormal protein expression 
(isolated absence of MSH6 or PMS2 or combined absence of 
MSH2/MSH6) are likely due to LS and need referral to Cancer 
Genetics.        
Additional Applications: 
The lifetime risk of endometrial cancer (EC) in women with LS 
is similar to the CRC risk.  As such, there is surging interest in 
screening EC’s for LS.  The National Comprehensive Cancer 
Network clinical practice guideline for uterine neoplasms 
recommends consideration of LS screening in EC patients 
<55-years-old, although the median age of patients detected 
in population-based screening is 60-years-old.  Pathology and 
Gynecologic Oncology at Iowa are currently working together 
to develop the best screening strategy for our patient population.  
MMR IHC is fairly sensitive (~67%) and highly specific for 
identifying LS in colorectal adenomas.  Screening for LS is also 
reasonable in other Lynch-associated tumors (e.g., sebaceous 
neoplasms, small intestinal cancers), especially in cases with a 
suspicious family history in which a CRC or EC is not available 
for testing.     
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Mismatch Repair Protein Immunohistochemistry in Lynch–Associated Neoplasms 
(Image 1) Duodenal cancer detected in the follow up of a patient with (Image 2) sebaceous carcinoma (hematoxylin-and-eosin, each 200x).  The patient had a colectomy 
17-years prior for colon cancer, and there was a strong family history of colon cancer.  (Image 3) Absent MSH2 (and MSH6) expression in the associated duodenal 
adenoma, with intact expression in stroma, a lymphoid aggregate, and non-neoplastic crypts and Brunner glands; (Image 4) Intact MLH1 (and PMS2) expression 
(immunoperoxidase, each 100x). This pattern of expression is most in keeping with Lynch syndrome (LS) due to a MSH2 mutation.  The occurrence of sebaceous 
neoplasms in LS is referred to as Muir-Torre syndrome.       
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Merkel cell carcinoma (MCC) is the 
designation for primary high-grade 
neuroendocrine carcinoma (HGNEC) 
of the skin.  It is a clinically aggressive 
tumor with 33-50% mortality at 5-years.  
1600 cases are diagnosed in the United 
States annually, a 400% rise over the last 
25 years (attributed to improved disease 
recognition and to an aging population that 
is more frequently immune suppressed).  
The diagnosis of MCC is often clinically 
delayed.  In an attempt to improve 
diagnosis, Heath and colleagues analyzed 
the clinical features in 195 MCC’s.(1)  
They coined the acronym AEIOU, which 
captures the disease’s key presenting 
features: Asymptomatic (i.e., non-tender), 
seen in 88%; Enlarging rapidly, 63%; 
Immunosuppression (chronic lymphocytic 
leukemia, transplant, HIV), 8%; Older 
than 50, 90%, and UV-exposed areas, 
81%.  Also of note, 98% of patients were 
white.  In addition to surgery, sentinel 
lymph node biopsy and radiation are 
often important components of patient 
treatment.  Chemotherapy is reserved for 
patients with high-stage disease, and it is 
not especially effective.  
 
Historical Background:
In 1972 Cyril Toker reported 5 cases of 
“trabecular carcinoma of the skin.”(2)  
Patients had a median age of 65, and tumors 
had been noted for 3 months to 2 years 
before biopsy.  Two patients experienced 
local recurrences, 3 had nodal metastases, 
and 1 died of disease.  Three cases had 
originally been diagnosed as “cutaneous 
metastases from anaplastic visceral 
cancers.”  Toker subsequently reported the 
presence of neurosecretory granules seen 
on electron microscopy in these tumors and 
suggested a relationship with Merkel cells 
(mechanoreceptors within the epidermis).  
“Merkel cell carcinoma” entered the 
Merkel Cell Carcinoma is Caused by a Polyomavirus, 
Which can be Detected by Routine Immunohistochemistry
lexicon in 1980.  In 1985 Moll and Franke 
identified the protein that would soon come 
to be known as cytokeratin 20, which in 
addition to being expressed by intestinal 
epithelium was found in 9 of 9 MCC’s and 
0 of 17 pulmonary neuroendocrine tumors 
(NET’s).(3)    
Histologic Features:
MCC is a dermal-based tumor that is 
generally recognizable on the H&E as 
a HGNEC.  Some cases resemble small 
cell carcinoma of the lung but tumors 
are especially apt to show “intermediate 
cell” morphology (i.e., slightly larger cell 
size, more open chromatin, inconspicuous 
but identifiable nuclei) (see Image 1).  
Most cases are pure NEC’s but around 
5% are “combined” with another non-
melanoma skin tumor (i.e., overlying 
actinic keratosis or squamous cell 
carcinoma [SCC] in situ; admixed with 
SCC or basal cell carcinoma; or with 
intratumoral squamous differentiation) 
(see Image 2).  The principal differential 
diagnosis is cutaneous metastasis from a 
visceral HGNEC, especially from lung, 
and diagnosis can be difficult in crushed 
small biopsies (where a distinction 
from lymphoma, for example, can be 
challenging).  
Immunohistochemical Features:
Routine immunohistochemistry (IHC) is 
helpful on both of these fronts.  MCC’s 
mark with antibodies to broad spectrum 
keratins and general neuroendocrine 
markers.  In addition, approximately 95% 
of tumors express CK20, which is often 
perinuclear/dot-like (see Image 3).  TTF-1 
expression in MCC is seen in less than 
1% of cases.  Pulmonary HGNEC’s, on 
the other hand, are nearly always TTF-
1-positive/CK20-negative.  There is 
very little data on the immunophenotype 
of non-pulmonary, visceral HGNEC’s, 
although primary parotid HGNEC’s 
are known to often express CK20 (60-
80%), while HGNEC’s of the uterine 
cervix occasionally do (10-20%).  CK20 
expression by non-MCC HGNEC’s and 
CK20-negative MCC’s are challenges, 
and additional diagnostically useful 
immunostains would be welcome.
Merkel Cell Polyomavirus Causes 
Merkel Cell Carcinoma:  
In 1994 Drs. Yuan Chang and Patrick 
Moore identified a herpesvirus (human 
herpesvirus 8; Kaposi-sarcoma-associated 
herpesvirus) in Kaposi sarcoma.  They 
hypothesized that MCC, a tumor that 
typically affects the elderly and with a 
very large relative risk in the immune 
suppressed, would also be associated with 
an oncovirus.  Utilizing a technique they 
termed “digital transcriptome subtraction” 
in which they sequenced cDNA libraries 
constructed from 4 tumors, aligned the 
resulting sequences against NCBI human 
genome reference sequences, and searched 
for an infectious agent among the rare 
non-aligned sequences, they discovered 
a single sequence with high homology 
to the large T (LT) antigen of monkey 
and human polyomaviruses.(4)  They 
subsequently identified the virus, which 
they termed Merkel Cell Polyomavirus 
(MCPyV), by polymerase chain reaction 
(PCR) in 8 of 10 (80%) MCC’s and 
only 9 of 84 (11%) control tissues.  In 
tumor samples, MCPyV was clonally 
integrated into host DNA.  The group next 
demonstrated a characteristic mutation 
pattern in the LT antigen of the integrated 
virus, which abolished the virus’s ability 
to productively replicate (and thus destroy 
the host cell) without affecting the 
oncogenic properties of its RB-binding 
domain.(5)  Since the initial description, 
MCPyV has been detected by PCR in 
MCC by ~20 groups in ~600 tumors, 
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generally in the 80% range reported by 
Chang and Moore.  A notable outlier was a 
group of Australian tumors, in which virus 
was detected in only 5 of 21 (24%).(6) 
Epidemiology of Merkel Cell 
Polyomavirus:
About 60% of the population demonstrates 
MCPyV seropositivity.  Schowalter et al 
were able to detect full-length, wild-type 
MCPyV genomes from skin swabs of 14 
of 35 (40%) healthy adult volunteers.(7)  
Infection is believed to be asymptomatic.  
Although MCPyV is prevalent in the 
population, MCC is rare because it 
requires both clonal integration of the 
virus and the characteristic mutation in the 
LT antigen described above.    
Merkel Cell Polyomavirus 
Immunohistochemistry:  
In an effort to lend additional support 
to the etiopathogenic role of MCPyV 
in MCC, Chang and Moore’s group 
developed a monoclonal antibody (MoAb) 
to the virus’s LT antigen (clone CM2B4).
(8)  They detected LT protein expression 
in 21 of 30 (70%) CK20-positve MCC’s 
and 0 of 4 pulmonary HGNEC’s, 0 of 
142 hematolymphoid neoplasms, and 0 
of 31 non-neoplastic lymphoid tissues.  
Similar to the MCPyV PCR data, LT 
antigen has been detected by CM2B4 
IHC in ~80% of MCC’s.  Interestingly, 
the few dozen “combined” MCC’s tested 
to date have been uniformly negative.  
Other skin cancers are also negative, and 
other HGNEC’s, including 7 primary 
parotid tumors, have been negative in 
most groups’ hands.  Again, a cohort of 
Australian tumors is the outlier, with 
Paik and colleagues reporting LT antigen 
expression in 19 of 89 (21%) MCC’s.(9)  
The CM2B4 antibody is commercially 
available from Santa Cruz Biotechnology 
(Santa Cruz, CA).
A New Monoclonal Antibody Improves 
Detection of Merkel Cell Polyomavirus:
I recently had the opportunity to participate 
in the evaluation of a new monoclonal 
antibody to the LT antigen of MCPyV.  This 
project intersected with my interests in 
gastrointestinal (GI) neoplasia, NET’s, and 
diagnostic IHC.  The antibody Ab3, raised 
against the N-terminal 260 residues of LT, 
was produced in the MoAb core facility of 
the Dana-Farber Cancer Institute, directed 
by my former colleague James DeCaprio.  
Dr. DeCaprio is a virologist whose 
laboratory focuses on the polyomavirus 
SV40.  He hypothesized that >80% of 
MCC’s are caused by MCPyV and that a 
better MoAb would improve the detection 
rate.  While LT antigen expression as 
detected by CM2B4 was found in 81% 
(46/57) of MCC’s, the rate of positivity 
with Ab3 was 97% (56/58) (see Image 
4).(10)  Ab3 IHC was negative in 10 GI 
HGNEC’s, 8 small cell lung cancers, 
and 7 non-neoplastic lymphoid tissues.  
Interestingly, TP53 mutations were detected 
in both Ab3-negative MCC’s.  
Summary:                   
MCC is an aggressive neuroendocrine 
skin tumor, increasing in incidence.  Most 
cases are associated with MCPyV, which 
is clonally integrated and contains LT 
antigen truncating mutations.  MCPyV 
LT antigen can be detected by IHC, 
which may be useful to confirm the 
diagnosis of MCC in rare CK20-negative 
tumors and to either confirm or argue 
against the diagnosis in CK20-positive 
tumors in which a non-MCC HGNEC 
is a reasonable possibility.  Using the 
new MoAb Ab3, LT antigen expression 
was found in 97% of 58 MCC’s.  It will 
be interesting to see the results of Ab3 
staining in Australian cases, which up 
to now appear to largely represent a 
closely related but distinct tumor type.  
Finally, there are likely other tumors or 
inflammations out there just waiting to 
be “solved” with pathogen discovery by 
genomic subtraction.       
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Image 1. Merkel cell carcinoma (MCC): 
high-grade neuroendocrine carcinoma 
with “intermediate cell” differentiation.
Image 2. “Combined” MCC: MCC 
associated with overlying squamous 
cell carcinoma in situ 
Image 3. Typical CK20 perinuclear/dot-
like expression in MCC
Image 4. Large T antigen expression in 
MCC detected by Ab3 immunohisto-
chemistry
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The Vysis ALK Break Apart FISH is a qualitative test to detect rearrangements involving 
the ALK gene via fluorescence in situ hybridization (FISH) in non-small cell lung 
cancer tissue specimens to aid in identifying those patients eligible for treatment with 
XALKORI® (crizotinib). 
NEW: BCR/ABL Quantitative
The BCR/ABL gene rearrangement is observed in CML, ALL, and, rarely, AML. A 
positive result indicates the presence of the Philadelphia chromosome, but the diagnosis 
of CML or ALL should be based on the presence of characteristic cellular abnormalities 
in bone marrow. In patients with ALL, the BCR/ABL rearrangement is associated with 
poor prognosis. Serial monitoring of assay values may provide a quantitative measure of 
tumor burden and response to therapy. Increasing levels of BCR/ABL are associated with 
clinical progression. Testing is performed on RNA from peripheral blood or bone marrow 
specimens using real time PCR. Results are calibrated and reported relative to the WHO 
International Standard as the percent international standard or %IS.
NEW: CEBPA Mutation Analysis
Somatic mutations of CEBPA are among the most common in acute myelogenous leukemia 
ranging from 5-14% of cases particularly in the former FAB M1 and M2 subtypes.  Along 
with having a normal karyotype, the majority of CEBPA-mutated cases have two distinct 
CEPBA mutations affecting different functional domains of the protein.  In the absence of 
other unfavorable mutations that mitigate CEBPA double-mutations, there is an associated 
favorable prognosis as measured by overall and disease-free survival.
NEW: Dysferlin Gene Sequence Analysis
Mutations in the dysferlin gene (DYSF) on chromosome 2p13, are at the origin 
of dysferlinopathies, a heterogeneous group of rare autosomal recessive inherited 
neuromuscular disorders. The main clinical presentations are the distal-onset muscular 
dystrophy called Miyoshi myopathy and the proximal-onset form LGMD2B, both 
characterized by progressive muscle weakness, usually appearing in the second decade, 
and highly elevated serum creatine kinase (CK) levels. Mutational analysis of DYSF 
is complicated by the large mutational spectrum and a high proportion of “private” 
mutations, with the recurrent difficulty of interpreting novel DYSF sequence variants, in 
particular putative splicing and missense variants.
The 55 coding exons and the flanking intronic regions of the DYSF gene are amplified 
by PCR and sequenced in both directions.  The reference sequence with which patient 
sequences are compared is NM_003494.3 (in some case with alternative exons HGVS 
recommended).
NEW: Epstein Barr Virus (EBV) by Quantitative PCR
This test is intended for use in conjunction with clinical presentation and other laboratory 
markers as an indication of an EBV-related tumor. This test is also used as an aid in 
accessing viral response to treatment as measured by changes in EBV DNA levels. Testing 
is performed using real time PCR. Results are calibrated to the WHO International Standard 
and will be reported in international units (IU)/ml and the log transformed values. EBV 
PCR should not be used to diagnose or confirm primary or reactivated mononucleosis; 




Please visit our website and test 
directory for more detailed test 
information and to download forms at:
www.healthcare.uiowa.edu/uidl
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NEW: Hepatitis E Virus PCR
Hepatitis E virus (HEV) causes sporadic and epidemic forms 
of acute hepatitis. It is responsible for waterborne hepatitis 
epidemics in developing countries, while in the United States, it 
is usually diagnosed in recent travelers to endemic areas (India, 
Asia, Africa, and Central America). It can infect animals, and 
pigs are an important reservoir. One clinical concern is the 
development of chronic HEV infection in solid organ transplant 
patients. Hepatitis E IgG antibodies can be detected particularly 
during the acute phase, but in most patients IgG antibodies are 
short lived. Molecular testing for the viral RNA may be used if 
there is concern for chronic HEV infection.
NEW:  KIT Mutation  Analysis (GIST and melanoma)
The principle use of this test is to detect mutations in patients 
with gastrointestinal stromal tumor (GIST) and melanoma. For 
acute myeloid leukemia (AML) testing, please order KITAML 
Mutation Analysis (LAB7659). This test is not intended to detect 
D816 mutation in bone marrow for mast cell disease or minimal 
residual disease, see KITMAST Mast Cell Disease (LAB7567).
NEW: KIT AML Mutation Analysis
KIT (also known as c-KIT) belongs to a family of type III 
receptor tyrosine kinases. Activating KIT mutations are seen 
in 70–80% of gastrointestinal stromal tumors (GISTs), ~95% 
mastocytosis, 25% germ cell tumor, 2% melanoma and a subset 
of acute myeloid leukemia (AML).  The location and type of 
KIT mutations are associated with prognosis and response to 
imatinib therapy.
Testing of KIT mutations can be utilized:
1. To assist in diagnosis of GIST, melanoma and AML.
2. To assist in therapy selection for GIST and melanoma.
3. To assist in prognosis of GIST and AML.
KIT AML Mutation Analysis detected exons related to patients 
with AML. If patient has GIST or melanoma, order KIT Mutation 
Analysis (LAB7660). This is a sequence-based assay. This test 
is not intended to detect D816 mutation in bone marrow for 
mast cell disease or minimal residual disease (see KIT Mutation 
(D816V) Mast Cell Disease (LAB7567).
NEW: KIT Mutation (D816V) MAST Cell Disease
Activating point mutations at codon 816 in the KIT receptor 
tyrosine kinase are seen in the majority of patients with systemic 
mast cell disease and can help in diagnosis of this disorder.
NEW: ISPD (Isoprenoid synthase domain 
containing)
Mutations in the isoprenoid synthase domain containing (ISPD) 
gene (HGNC 37276) have been shown recently to cause Walker-
Warburg syndrome (WWS). WWS is characterized by congenital 
muscular dystrophy, hydrocephalus, agyria, retinal dysplasia, 
with or without encephalocele.
NEW: MatBA® – CLL Array – CGH Assay
Loss of specific chromosomal loci is associated with prognostic 
information for CLL patients. MatBa–CLL Array–CGH Assay 
provides for a more comprehensive panel of chromosomal loci 
information not available in a single test.
NEW: NRAS Mutational Analysis
The presence of an oncogenic mutation in codons 12, 13, or 61 of 
NRAS is indicative of a tumor that may respond to drugs targeted 
at genes downstream of NRAS in the mitogen activating protein 
kinase (MAPK) signaling cascade, as in malignant melanoma cases. 
In contrast, mutations in NRAS can inhibit therapeutic response 
to EGFR-targeted therapies in patients with metastatic colorectal 
cancer.  NRAS mutations are found in the more aggressive variant 
of chronic myelogenous leukemia (CMML) and may predict 
response to farnesyl transferase inhibitors therapy in acute myeloid 
leukemia (AML).
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Faculty 
RESEARCH PUBLICATIONS
Evaluation of the Bruker Biotyper 
and Vitek MS matrix-assisted laser 
desorption ionization-time of flight mass 
spectrometry systems for identification 
of nonfermenting gram-negative bacilli 
isolated from cultures from cystic 
fibrosis patients.
Marko DC, Saffert RT, Cunningham SA, 
Hyman J, Walsh J, Arbefeville S, Howard 
W, Pruessner J, Safwat N, Cockerill FR, 
Bossler AD, Patel R, Richter SS.
J Clin Microbiol. 2012 Jun;50(6):2034-9. 
doi: 10.1128/JCM.00330-12. Epub 2012 
Apr 11.
Identification of a Novel, Recurrent 
SLC44A1-PRKCA Fusion in Papillary 
Glioneuronal Tumor.
Bridge JA, Liu XQ, Sumegi J, Nelson 
M, Reyes C, Bruch LA, Rosenblum M, 
Puccioni MJ, Bowdino BS, McComb RD.
Brain Pathol. 2012 Jun 22. doi: 10.1111/
j.1750-3639.2012.00612.
Cortisol and inflammatory processes 
in ovarian cancer patients following 
primary treatment: Relationships with 
depression, fatigue, and disability.  
Schrepf A, Clevenger L, Christensen 
D, Degeest K, Bender D, Ahmed A, 
Goodheart MJ, Dahmoush L, Penedo 
F, Lucci JA 3rd, Ganjei-Azar P, Mendez 
L, Markon K, Lubaroff DM, Thaker PH, 
Slavich GM, Sood AK, Lutgendorf SK.
Brain Behav Immun. 2012 Aug 5. Epub. 
PMID 22884960.
Social influences on clinical outcomes of 
patients with ovarian cancer.
Lutgendorf SK, De Geest K, Bender D, 
Ahmed A, Goodheart MJ, Dahmoush L, 
Zimmerman MB, Penedo FJ, Lucci JA 
3rd, Ganjei-Azar P, Thaker PH, Mendez 
L, Lubaroff DM, Slavich GM, Cole SW, 
Sood AK.
J Clin Oncol. 2012 Aug 10;30(23):2885-
90. 
Consensus statement on effective 
communication of urgent diagnoses and 
significant, unexpected diagnoses in 
surgical pathology and cytopathology 
from the College of American 
Pathologists and Association of 
Directors of Anatomic and Surgical 
Pathology.
Nakhleh RE, Myers JL, Allen TC, 
DeYoung BR, Fitzgibbons PL, Funkhouser 
WK, Mody DR, Lynn A, Fatheree LA, 
Smith AT, Lal A, Silverman JF.
Arch Pathol Lab Med. 2012 
Feb;136(2):148-54.Erratum in: Arch 
Pathol Lab Med. 2012 Apr;136(4):342
Effect of combined locally delivered 
growth factors and systemic sildenafil 
citrate on microrecanalization in 
biodegradable conduit for vas deferens 
reconstruction.
Rosevear HM, Krishnamachari Y, Ariza 
CA, Mallapragada SK, Salem AK, Griffith 
TS, De Young BR, Wald M.
Urology. 2012 Apr;79(4):967.e1-4. 
Relationship between HER-2 
overexpression and brain metastasis in 
esophageal cancer patients.
Abu Hejleh T, Deyoung BR, Engelman E, 
Deutsch JM, Zimmerman B, Halfdanarson 
TR, Berg DJ, Parekh KR, Lynch WR, 
Iannettoni MD, Bhatia S, Clamon G.
World J Gastrointest Oncol. 2012 May 
15;4(5):103-8.
Interobserver reliability in the 
histopathological diagnosis of 
cartilaginous tumors in patients with 
multiple osteochondromas.
de Andrea CE, Kroon HM, Wolterbeek 
R, Romeo S, Rosenberg AE, De Young 
BR, Liegl B, Inwards CY, Hauben E, 
McCarthy EF, Idoate M, Athanasou NA, 
Jones KB, Hogendoorn PC, Bovée JV.
Mod Pathol. 2012 Sep;25(9):1275-83. doi: 
10.1038/modpathol.2012.78. 
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Ascending aortic graft thrombosis 
and diffuse embolization from early 
endoluminal Aspergillus infection.
Calcaterra D, Bashir M, Gailey MP.
Ann Thorac Surg. 2012 Oct;94(4):1337-9. 
doi: 10.1016/j.athoracsur.2012.02.099
Accuracy of fine-needle aspiration and 
imaging in the preoperative workup 
of salivary gland mass lesions treated 
surgically.
Tryggvason G, Gailey MP, Hulstein 
SL, Karnell LH, Hoffman HT, Funk GF, 
Jensen CS, Van Daele DJ.
Laryngoscope. 2012 Sep 18. doi: 10.1002/
lary.23613. Epub. PMID 22991236.
Clinical decision support of therapeutic 
drug monitoring of phenytoin: 
measured versus adjusted phenytoin 
plasma concentrations.
Krasowski MD, Penrod LE.
BMC Med Inform Decis Mak. 2012 Feb 
14;12:7.
Successful Integration of the Histology 
Core Laboratory in Translational 
Research.
Gibson-Corley KN, Hochstedler C, Sturm 
M, Rogers J, Olivier AK, Meyerholz DK.
J Histotechnol. 2012 Apr 1;35(1):17-21.
Genetically modified species in 
research: Opportunities and challenges 
for the histology core laboratory.
Olivier AK, Naumann P, Goeken A, 
Hochstedler C, Sturm M, Rodgers JR, 
Gibson-Corley KN, Meyerholz DK.
J Histotechnol. 2012 Jul 1;35(2):63-67
Ecology: Bat deaths from wind turbine 
blades.
Capparella A, Loew S, Meyerholz DK.
Nature. 2012 Aug 2;488(7409):32. doi: 
10.1038/488032d. 
Pancreatic and Biliary Secretion Are 
Both Altered in Cystic Fibrosis Pigs.
Uc A, Giriyappa R, Meyerholz DK, 
Griffin M, Ostedgaard LS, Tang X, Abu-
El-Haija M, Stoltz DA, Ludwig P, Pezzulo 
AA, Abu-El-Haija M, Taft PJ, Welsh MJ.
Am J Physiol Gastrointest Liver Physiol. 
2012 Aug 30.
Abnormal endocrine pancreas function 
at birth in cystic fibrosis ferrets.
Olivier AK, Yi Y, Sun X, Sui H, Liang 
B, Hu S, Xie W, Fisher JT, Keiser NW, 
Lei D, Zhou W, Yan Z, Li G, Evans TI, 
Meyerholz DK, Wang K, Stewart ZA, 
Norris AW, Engelhardt JF.
J Clin Invest. 2012 Oct 1; 122(10):3755-
68.
The role of LEF1 in endometrial gland 
formation and carcinogenesis.
Shelton DN, Fornalik H, Neff T, Park 
SY, Bender D, DeGeest K, Liu X, Xie 
W, Meyerholz DK, Engelhardt JF, 
Goodheart MJ.
PLoS One. 2012;7(7):e40312.
Infantile onset CMT2D/dSMA V in 
monozygotic twins due to a mutation 
in the anticodon-binding domain of 
GARS.
Eskuri JM, Stanley CM, Moore SA, 
Mathews KD.
J Peripher Nerv Syst. 2012 Mar;17(1):132-
4. doi: 10.1111/j.1529-8027.2012.00370.x.
LMNA variants cause cytoplasmic 
distribution of nuclear pore proteins in 
Drosophila and human muscle.
Dialynas G, Flannery KM, Zirbel LN, 
Nagy PL, Mathews KD, Moore SA, 
Wallrath LL.
Hum Mol Genet. 2012 Apr 1;21(7):1544-56.
Sudden Death and Myocardial Lesions 
after Damage to Catecholamine 
Neurons of the Nucleus Tractus Solitarii 
in Rat.
Talman WT, Dragon DN, Jones SY, 
Moore SA, Lin LH.
Cell Mol Neurobiol. 2012 Apr 8.
ISPD loss-of-function mutations disrupt 
dystroglycan O-mannosylation and 
cause Walker-Warburg syndrome.
Willer T, Lee H, Lommel M, Yoshida-
Moriguchi T, de Bernabe DB, Venzke 
D, Cirak S, Schachter H, Vajsar J, Voit 
T, Muntoni F, Loder AS, Dobyns WB, 
Winder TL, Strahl S, Mathews KD, 
Nelson SF, Moore SA, Campbell KP.
Nat Genet. 2012 May;44(5):575-80.
Very early recurrence of anti-
Phospholipase A2 receptor-positive 
membranous nephropathy after 
transplantation.
Blosser CD, Ayalon R, Nair R, Thomas C, 
Beck LH Jr.
Am J Transplant. 2012 Jun;12(6):1637-42. 
doi: 10.1111/j.1600-6143.2011.03957.x. 
Recent Iowa trends in sudden unexpected 
infant deaths: the importance of public 
health collaboration with medical 
examiners’ offices.
Harris ML, Massaquoi D, Soyemi K, 
Brend SM, Klein D, Pentella M, Kraemer 
J, Nashelsky M, Schmunk G, Smith T, 
Pleva A.
Am J Forensic Med Pathol. 2012 
Jun;33(2):113-8.
Numerous skin-colored papules on the 
face and neck.
Hochwalt PC, Asarch A, Stone MS, 
Fairley JA.
Arch Dermatol. 2012 Jul;148(7):849-54.
Resident rounds: Part III generalized 
linear porokeratosis.
Pietras TA, Asarch A, Fernandez KH, 
Hochwalt PC, Ritchie J, Stone MS.
J Drugs Dermatol. 2012 Jun;11(6):772-3. 
Acquired Epidermodysplasia 
Verruciformis in a Child with Atopic 
Dermatitis.
Fernandez KH, Rady P, Tyring S, Stone MS.
Pediatr Dermatol. 2012 Sep 3. doi: 
10.1111/j.1525-1470.2012.01822.x.
Nonhealing ulcer of the left fifth finger.
Hochwalt PC, Swick BL, Liu V.
Arch Dermatol. 2012 Jul;148(7):849-54. 
Sweet syndrome with systemic 
inflammatory response syndrome.
Vanourny J, Swick BL.
Arch Dermatol. 2012 Aug 1;148(8):969-70.
Erythema Migrans: A Spectrum of 
Histopathologic Changes.
Wilson TC, Legler A, Madison KC, 
Fairley JA, Swick BL.
Am J Dermatopathol. 2012 Jun 20.
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education during the past 
year.  Dr. Barry Deyoung, 
Interim Department Head, 
comments on Dr. Krasowski’s 
award:
Dr. Krasowski has 
significantly contributed to 
medical student education 
at the Carver College of 
Medicine.  He serves as the 
clerkship director for the 
“Laboratory Medicine in 
Clinical Practice” (for M3 
and M4 students) which not 
only involves approximately 
50 hours of direct student 
contact, but also significant administrative work.  
He has led a major overhaul of this course with significant 
improvement in student evaluations.  He also lectures to M2 
medical students in the Medical Pathology course.  In addition, 
in the past year, he served on one of the Mechanisms of Health 
and Disease (MOHD) work groups for the curriculum revision 
process.  He is a constant advocate for medical student education 
and an excellent role model in this regard.”
USCAP 2012 Features UI Department of Pathology
The University of Iowa Department of Pathology was featured in a 
video presentation at the 2012 United States & Canadian Academy 
of Pathology (USCAP) meeting held in March in Vancouver. 
The five-minute video was part of USCAP-TV, an innovative 
initiative to raise the visibility of best practices in the field.  Our 
feature video entitled “Balanced Leadership – University of Iowa 
Pathology” can be viewed online on YouTube. 
Robert A. Robinson, MD, PhD Publishes 2nd 
Pathology Textbook
Dr. Robert A. Robinson, Professor 
of Pathology and Oral Pathology, 
Radiology and Medicine, and Medical 
Director of the University of Iowa 
Diagnostic Laboratories has co-authored 
a second textbook “AFIP ATLAS of 
TUMOR PATHOLOGY Series 4:  
Tumors and Cysts of the Jaw”.  
Authored together 
with Dr. Steven 
Vincent, 
Department 
Head of Oral Pathology, Radiology and 
Medicine, University of Iowa College 
of Dentistry,  this book follows Dr. 
Robinson’s first book “Head and Neck 
Pathology:  Atlas for Histologic and 
Cytologic Diagnosis”. 
New Faculty Join Our Team
Please join us in welcoming our two newest faculty members 
Dr. Bradley Ford, Clinical Assistant Professor, Associate 
Director of Microbiology and Dr. Megan Samuelson, Clinical 
Assistant Professor, Surgical Pathology and Cytopathology, 
Subspecialty – Obstetrics and Gynecologic Pathology.   We 
are very pleased to have them join our team in serving the 
physicians and patients of UIHC as well as our UI Diagnostic 
Laboratories outreach clients. 
Outstanding Educator Award 2012 
Congratulations to Dr. Krasowski for his recent receipt of the 
2012 Carver College of Medicine, Department of Pathology, 
Outstanding Educator Award.  Dr. Krasowski received this 
award due to his significant contributions to medical student 




Bradley Ford, MD, PhD
Phone:  319-356-2990
Email:  bradley-ford-1@uiowa.edu
Faculty AWARDS AND RECOGNITIONS
Matthew Krasowski, MD, PhD
Clinical Associate Professor of Pathology
The lab also develops new tests in the areas of genetics and 
infectious disease, such as ISPD and DYSF gene sequencing for 
patients with suspected inherited neuromuscular disease, and a 
qualitative PCR test for hepatitis E virus (HEV).  Details about 
these and other molecular tests now available are provided in 
this issue.  More new tests are in development—stay tuned.
Expansion of Test Development Capability  
continued from page 1
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George D. Penick Award Presented to 
Outstanding Pathology Residents
The George D. Penick Award for Excellence in Education had two 
recipients in 2012: Michael Gailey, DO and John Blau, MD. The 
Penick award is given annually to a pathology resident who displays 
excellence in and commitment to the education and teaching of 
medical students, peers and clinical colleagues. 
The awards were presented to Dr. Gailey and Dr. Blau by Leslie 
Bruch, MD, Vice Chair of Educational Affairs.
Michael Gailey, DO and  
Leslie Bruch, MD
John Blau, MD and Leslie Bruch, MD
Pictured: Dr. Frank Mitros, Dr. Bryan Steussy.
2012-2013 Co-Chief Residents Selected
Congratulations are extended to the 2012-2013 Co-Chief 
Residents:  Bryan Steussy, MD and Thomas Wilson, MD. A 
special thank you goes to Drs. Michael Gailey and Joel Miron 
for serving as the 2011-2012 Co-Chief Residents.
For more information about our residency 
program, please contact: 
Residency Program AWARDS
RESIDENCY LEADERS







Assistant Residency Program 
Director 
Thomas J. Raife, MD










Resident Teaching Award 2012
The 2012 recipient of the Resident Teaching Award is Frank 
Mitros, MD.  This award is given each year to a faculty member 
in the Department of Pathology who displays exemplary 
teaching and mentoring skills while working with the residents. 
Bryan Steussy presented Dr. Mitros an award certificate at the 
Farewell Dinner for Pathology Residents and Fellows held on 
June 8, 2012. His name will also be added to the teaching award 
plaque displayed in Pathology Administration.
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It has almost been over 2 years since my appointment as the Development Officer for the 
Department of Pathology.  I have had the pleasure of meeting many engaging faculty, staff, alumni 
and friends of the department and I have discovered a common thread they all share, a thread 
that is simply referred to as “the Iowa way.”   Whether it was a kind welcome, a dedicated faulty 
member or help in the lab, the Iowa way makes you feel like you are always in the right place and 
among friends.  There are many more stories to be told and memories to be revisited.  I welcome 
the opportunity to have you share with me your personal experience with “the Iowa Way.” 
  
As you start to prioritize your year-end donations, or think about your future ones, please consider 
supporting the UI Department of Pathology.  Private support is as important as ever right now.   
What areas would be most meaningful for you to support?  Is it the brilliant, young students?  
Cutting edge research or dedicated faculty? Dedicated faculty?  
Below are some of the most common ways you can support the UI Department of Pathology, often 
while realizing tax benefits. No matter how – or how much – you give, your generosity will make 
a difference in the lives and work of UI students, educators, and all whom the University serves.
 
Annual Giving – Ongoing, sustaining gifts that enable UI areas to embrace opportunities and 
meet challenges 
Planned Giving – Gifts carefully planned to help you meet your philanthropic and financial goals 
Corporate and Foundation Relations - Relationships with corporations and foundations that 
result in philanthropic benefit for The University of Iowa 
Matching Gifts – A way to multiply your generosity through your employer’s matching gift 
program 
Honorary and Memorial Gifts – Honoring someone special with a gift supporting the UI 
Stock Gifts – Supporting the UI with gifts of appreciated stocks and mutual funds 
Cash gifts – Outright gifts made via cash, check, credit card, or other means 
Real and personal property – Real estate and marketable items of personal property 
Online giving – Gifts made through www.givetoiowa.org
 
To learn more about The University of Iowa Foundation, and how gifts from alumni and friends 
support students and faculty in the UI Department of Pathology, please visit www.uifoundation.
org or contact me at shelly-mott@uiowa.edu, (319) 467-3668 or toll-free 800-648-6973.
No matter 




will make a 
difference...
A Letter from UI Foundation
Partners in Supporting the Department of Pathology
Shelly J. Mott
Director of 
Development, Roy J. 
and Lucille A. Carver 
College of Medicine/
University of Iowa 
Hospitals and Clinics, 
The University of 
Iowa Foundation
200 Hawkins Drive 5231 RCP
Iowa City, IA 52242-1009
